This Pharma Stock Is Today’s Worst in the S&P 500. Here’s Why. - Barron's
1. WST stock fell 31% after poor earnings outlook. 2. 2025 net sales projected below analyst expectations at $2.875B-$2.905B. 3. Adjusted earnings forecast also missed expectations at $6-$6.20 per share. 4. The company faces a $75M currency headwind affecting sales. 5. Partnership terminations with glucose monitoring clients impact future revenue.